PUF Ventures Inc. (CSE:PUF, Frankfurt:PU3, OTCPK:PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to announce that the Company has appointed Dr. Cezar Khursigara to its Advisory Board.
PUF Ventures Inc. (CSE:PUF, Frankfurt:PU3, OTCPK:PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to announce that the Company has appointed Dr. Cezar Khursigara to its Advisory Board. The Advisory Board will oversee all areas related to PUF Ventures’ medical cannabis research and development initiatives.
“We are honoured to have Dr. Khursigara join PUF’s Advisory Board,” said Derek Ivany, President and CEO of the Company. “Dr. Khursigara is a widely respected and accomplished researcher in the areas of microbiology and biotechnology. He brings a cross disciplinary approach to our team and will play an integral role as we develop our own cannabis strains and proprietary genetics. This is an important appointment for our Company as we pursue production licenses in Canada and with our partner Solaris Nutraceuticals in Australia.”
Dr. Khursigara is a leading researcher focused on microbiology and biotechnology applications. He is an Associate Professor in the Department of Molecular and Cellular Biology and Director of the Molecular Imaging and Mass Spectrometry Facilities at the University of Guelph. In 1999, Dr. Khursigara received a Bachelor’s Degree from Ryerson University in Chemistry and Biology, and in 2005 he received a Doctorate in Microbiology and Immunology from McGill University. Dr. Khursigara has trained at the National Institutes of Health in Bethesda Maryland where he conducted post-doctoral research at the National Cancer Institute. Dr. Khursigara is funded by the Natural Science and Engineering Research Council of Canada, the Canadian Institutes of Health Research and the Ontario Ministry of Agriculture, Food and Rural Affairs.
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., an advanced applicant for an ACMPR license. Solaris Nutraceuticals is building the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.